Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRX1 CBD for chemotherapy-induced peripheral neuropathy pain
ISRCTN15275553Phase 2Recruiting
- Sponsor
- University of Edinburgh
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of MRX1 and Placebo-COD Research Private Ltd in chemotherapy-induced peripheral neuropathy (CIPN) (2 arms), sponsored by University of Edinburgh. Primary endpoints: Sensory peripheral neuropathy and Anterior cingulate cortex resting-state functional connectivity. Started May 2026; status: recruiting.
02
Drugs
MRX1Placebo-COD Research Private Ltd
03
Conditions
chemotherapy-induced peripheral neuropathy (CIPN)
Beyond the preview
Go deeper on ISRCTN15275553.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN15275553.